Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
2(100.0%)
2Total
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07562243Not Yet Recruiting

Project PHOENIX: Molecular Signatures of Burn Pit Exposure

Role: lead

NCT05626712Phase 1Recruiting

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

Role: lead

NCT06053242Phase 1Recruiting

Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

Role: lead

NCT07137559Unknown

CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

Role: lead

All 4 trials loaded